Kodiak Sciences starts Phase 3 trial for KSI-501 to treat diabetic macular edema, aiming to outperform aflibercept.
Kodiak Sciences has initiated the global Phase 3 ALTO trial for KSI-501, a bispecific therapy for diabetic macular edema (DME). The trial seeks to demonstrate KSI-501's superiority over aflibercept by offering improved vision and longer-lasting effects with fewer injections. This development follows positive Phase …